Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Clonal Evolution × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

pembrolizumab 1127 Specimen Handling 797 Carboplatin 748 Magnetic Resonance Spectroscopy 723 Cyclophosphamide 720 Cisplatin 642 Nivolumab 628 Paclitaxel 562 Radiotherapy 534 Gemcitabine 498 Biopsy 484 Bevacizumab 423 Dexamethasone 399 Docetaxel 352 fludarabine 351 venetoclax 344 atezolizumab 329 Fluorouracil 326 Oxaliplatin 324 Capecitabine 320 Rituximab 315 durvalumab 302 Drug Therapy 299 Doxorubicin 285 Radiosurgery 285 Pemetrexed 281 Ipilimumab 276 Standard of Care 276 Blood Specimen Collection 274 Radiation 259

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡